InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Explore the full record of transactions filed by Emile Voest, Independent Director. Insider active across 1 companies, notably SANOFI. In total, 2 reports have been recorded. Total volume traded: €92k. The latest transaction was filed on 3 August 2023 — Acquisition. Regulator: AMF. The full history is openly available.
Declarations2 total
€46,272500 shares@ €92.5430.0000% mcap50.3% of flow
ActionEuronext Paris
2024DD966986·
Ideal exit: 29 Apr 2024 (T+270)
€45,670500 shares@ €91.340.0000% mcap49.7% of flow
ActionEuronext Paris
2022DD877433·
Ideal exit: 18 Sept 2023 (T+270)
2 of 2 declarations
About Emile Voest
Emile Voest is a Dutch physician-scientist and oncologist widely recognized for his expertise in precision oncology and for his governance roles in leading healthcare and research organizations. Since May 2022, he has served as an independent director of Sanofi and as a member of the company’s Scientific Committee. That appointment reflects a career built at the intersection of academic medicine, clinical innovation, and strategic leadership in cancer research. His background gives Sanofi strong scientific credibility, particularly in areas related to innovative oncology development and personalized medicine. In academia and hospital-based leadership, Emile Voest has been a professor of medical oncology at Utrecht University since 1999. He also served until 2021 as Executive Medical Director of the Netherlands Cancer Institute (NKI), one of the Netherlands’ leading cancer research and treatment centers. In that role, he helped advance translational research programs and supported the development of cutting-edge clinical initiatives. He continues to lead a research group at the NKI and the Oncode Institute, underlining his central position in Europe’s cancer innovation ecosystem. Voest also plays an important role in international scientific collaboration. He is Chairman of Cancer Core Europe, a network bringing together seven major European comprehensive cancer centers, and he founded Mosaic Therapeutics, where he now acts as strategic advisor. He is a co-founder and non-executive board member of the Hartwig Medical Foundation, which focuses on large-scale DNA analysis, and he serves on the board of the Center for Personalized Cancer Treatment. These roles highlight his deep expertise in molecular profiling, patient stratification, and the acceleration of precision oncology trials. Beyond these appointments, he has held leadership positions in major medical societies, including ESMO and ASCO. Holding a PhD in medicine from Utrecht University, Emile Voest represents the kind of scientific governance profile that is highly valuable for a global pharmaceutical company such as Sanofi, especially at the intersection of therapeutic innovation, clinical research, and academic partnerships.
